Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ACADIA Pharmaceuticals ( (ACAD) ) has issued an announcement.
In a recent regulatory filing, ACADIA Pharmaceuticals specified that certain information previously disclosed in Item 2.02 is being incorporated by reference into Item 7.01 of its Current Report on Form 8-K. The company also clarified that the information in this report, including the referenced exhibit, is not considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be automatically incorporated into other securities law filings, limiting potential liability and defining how this disclosure may be used in future regulatory documents.
The most recent analyst rating on (ACAD) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.
Spark’s Take on ACAD Stock
According to Spark, TipRanks’ AI Analyst, ACAD is a Outperform.
ACADIA Pharmaceuticals is well-positioned with strong financial performance, robust technical indicators, and strategic growth initiatives. The company’s reasonable valuation and positive earnings call sentiment further support its potential for future growth. However, operational efficiency improvements and market penetration challenges for DAYBUE remain areas to watch.
To see Spark’s full report on ACAD stock, click here.
More about ACADIA Pharmaceuticals
Average Trading Volume: 1,566,377
Technical Sentiment Signal: Buy
Current Market Cap: $4.53B
See more data about ACAD stock on TipRanks’ Stock Analysis page.